Axonova Medical LLC
Medtech · Private
Micro-tissue engineered nerve graft (µTENG), an injectable hydrogel-based tissue construct containing neurons and axon tracts to maintain distal nerve and muscle viability following major peripheral n
- Grants
- $6.4M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons | $224,562 | |
| Federal grant | Department of Health and Human Services · Phase I · Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons | $224,562 | |
| Federal grant | Department of Health and Human Services · Phase II · Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons | $1,083,394 | |
| Federal grant | Department of Health and Human Services · Phase II · Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons | $934,090 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Tissue Engineered Neuromuscular Interfaces from GalSafe Neurons. | $250,421 | |
| Federal grant | Department of Health and Human Services · Phase II · Generation of Tissue Engineered Nerve Grafts from GalSafe Porcine Neurons | $900,965 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Tissue Engineered Neuromuscular Interfaces from GalSafe Neurons | $766,451 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Tissue Engineered Neuromuscular Interfaces from GalSafe Neurons | $1,099,609 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Tissue Engineered Neuromuscular Interfaces from GalSafe Neurons | $902,542 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1991 | SymKardia, Inc. | — | $500K |
| 1992 | mFluiDx, Inc. | — | — |
| 1993 | Therapeutic Articulations, LLC | — | — |
| 1994 | Axonova Medical LLC | — | — |
| 1995 | UrSure Inc. | — | — |
| 1996 | Sojourn MedTech LLC | — | — |
| 1997 | Vitaliti Technologies Inc. | — | $21K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.